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Ischemia stimulates heart GLUT4 and GLUT1 translocation and glucose uptake 
in vivo. Stimulation of AMP-activated protein kinase (AMPK), an enzyme which 
mediates many of the effects of ischemia and which has been described as a cellular “fuel 
gauge,” with 5-aminoimidazole-4-carboxamide-l-ribofuranoside (AICAR) increases 2- 
deoxyglucose uptake and causes GLUT4 translocation in isolated cardiac papillary 
muscles. AMPK activation may also increase heart FFA uptake in vitro. In order to 
study the effects of specific cardiac AMPK activation on GLUT translocation and heart 
substrate metabolism in vivo, we selectively infused AICAR (12.5mg/min x 90 min) 
intra-arterially into the anterior, LAD region of the heart in 8 anesthetized dogs. AICAR 
increased myocardial AMPK activity 3-fold in the anterior region compared to the 
posterior control region. AICAR increased the myocardial uptakes of glucose (2.3 fold) 
and free fatty acids (1.4 fold), but did not alter heart lactate or oxygen uptake. AICAR 
did not alter the energetics of the myocardium and the myocardial concentrations of 
ATP, AMP, ADP and creatine phosphate, which normally regulate AMPK activity, did 
not change. Cell fractionation and subsequent immunoblotting of purified membrane 
fractions demonstrated AICAR-induced translocation of both GLUT4 (1.8 fold, p<0.002) 
and GLUT1 (1.7 fold, p<0.001) from intracellular membranes in sarcolemma. Therefore, 
AMPK activation by regional AICAR infusion increased myocardial glucose uptake and 
caused translocation of both GLUT1 and GLUT4 in vivo without changing cellular 
energetics. AICAR also modestly increased heart FFA uptake consistent with the known 
effect of AMPK to inhibit acetyl CoA carboxylase. These findings support the 

hypothesis that ischemia-induced increases in heart glucose uptake and glucose 




Myocardial Glucose Metabolism 
Cardiovascular disease, largely in the form of ischemic heart disease, is the 
leading cause of death in the developed world and in the next two generations will also 
become the leading cause of mortality in the third world. [Organization, 1998 #1] The 
past few decades have brought significant advances in the diagnosis and treatment of 
ischemic heart disease, both acutely during an episode of myocardial ischemia and 
chronically in optimizing cardiac function in the diseased heart and preventing further 
episodes of ischemia or cardiac death. Cholesterol control, hypertension management, 
procedures to revascularize ischemic myocardium, a wide array of pharmacological 
agents for hemodynamic control and other measures have given clinicians many tools to 
control ischemic heart disease. Recently, the understanding that clot formation plays a 
central role in the sudden loss of perfusion in myocardial ischemia has also led to the 
development of various thrombolytic therapies to quickly reperfuse myocardium. The 
observation that the revascularized, optimally loaded heart displays continued 
dysfunction following thrombolysis even while it remains viable has highlighted the role 
of metabolic derangement in myocardial ischemia and renewed interest in the metabolic 
changes that accompany ischemia and their contribution to contractile dysfunction. 
[Taegtmeyer, 1995 #3] 
Like all muscle, the heart functions to convert chemical energy into mechanical 
energy for pumping blood. The energy for this comes from metabolic substrate 
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oxidation which requires oxygenated blood and sufficient metabolite delivery. While 
the heart comprises just 0.5% of body weight it receives 4% of cardiac output and 
accounts for 10% of oxygen consumption. To meet its energy requirements the 300g 
heart uses a large amount of energy producing 35kg of ATP per day. [Willerson, 1995 
#2] The myocardium uses free fatty acids (FFA) and glucose for substrate during aerobic 
metabolism. The choice of substrate depends on arterial concentrations and is also 
influenced by hormones, workload and oxygen availability. [Willerson, 1995 #2] This 
leads to a preference for FFA during fasting, glucose after meals and lactate and FFA 
during exercise. The myocardium can also use ketone bodies and even amino acids to 
produce energy and under certain conditions also uses endogenous energy sources such 
as glycogen and triglycerides. [Taegtmeyer, 1995 #3] 
Glucose metabolism in myocardium, as in all tissues has two main components, 
glycolysis and glucose oxidation. Glycolysis can produce ATP without oxygen and 
while it usually contributes less than 10% of the ATP in non-ischemic conditions, it has 
a special role in maintaining the ion potential in the cell membrane. [Oliver, 1994 #4] 
Glucose is converted to pyruvate during glycolysis and once inside mitochondria, 
pyruvate dehydrogenase produces acetyl Co A which enters the TCA cycle generating 
reducing equivalents which are oxidized to produce ATP and water. Glucose can also be 
converted to glycogen under regulation of glycogen synthase or enter the pentose 
phosphate shunt to produce NADPH and ribose. Oxidation of fatty acids is the other 
main source of acetyl CoA production in mitochondria but is slightly less efficient than 
glucose oxidation requiring a greater amount of oxygen to produce each ATP. 
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During myocardial ishcemia, there is compromised tissue perfusion and oxygen 
delivery. However, residual anterograde perfusion and collateral blood flow maintains 
some residual availability of oxygen and substrate. [Willerson, 1995 #2] Anaerobic 
glycolysis becomes important in the production of a limited amount of ATP which along 
with residual glucose oxidation may or may not be capable of maintaining function. 
There is a shift away from aerobic fatty acid oxidation and an accumulation of fatty 
acids. [Lopaschuk, 1998 #5] In severe ischemia, catecholamines also stimulate lipolysis 
in adipocytes and contribute to a rise in fatty acids. [Goodwin, 1994 #8] This elevation in 
fatty acids may be arrythmogenic and contribute to depressed cardiac function. 
[Lopaschuk, 1998 #5; Goodwin, 1994 #8] Glycogen stores, are also depleted following 
severe ischemia. In addition, TCA intermediates are depleted when lactate, alanine and 
succinate accumulate and glutamate disappears. [Taegtmeyer, 1995 #3] 
Facilitative Glucose Transporters 
The greater utilization of glucose requires higher rates of glucose uptake. 
Enhanced uptake is accomplished through greater transport of glucose through facilitative 
glucose transporters. The family of facilitative glucose transporters (GLUTs) are passive 
carriers which transport glucose in an energy-independent system that moves down a 
concentration gradient. [Muekler, 1994 #9] Unlike the Na7glucose transport in intestine 
and kidney, the reaction is thermodynamically downhill and requires no energy. GLUTs 
mediate the exchange of glucose between the blood and cytoplasm and drive the balance 
of glucose concentrations between blood, the interstitial space and the cells. Once inside 
the cell, glucose is phosphorylated by hexokinase and in the absence of glucose-6- 
phosphatase in muscle, it remains within the cell. 
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Seven mammalian glucose transporter isoforms have been identified. They have 
12 membrane spanning helices with about half of the amino acid residues within the 
phospholipid bilayer of cellular membranes. [Stephens, 1995 #10] They exhibit tissue 
specificity and developmental related expression and in the adult mammalian heart, 
GLUT4 and GLUT1 are the primary isoforms expressed. [Fischer, 1997 #21] In heart and 
skeletal muscle, GLUT1 mRNA and protein decrease during development while GLUT4 
show increases. [Wang, 1991 #12; Santalucia, 1992 #13] GLUT1 is found primarily in 
cardiac myocytes of the ventricle and it controls basal glucose utilization when insulin 
concentrations are low and there is normal work demand. Studies in brain show that the 
Km of GLUT1 is ImM and thus GLUT1 has transport activity at normal glucose 
concentrations of approximately 4-8mM. [Stryer, 1995 #84; Holloszy, 1996 #19] 
GLUT4 has a Km of 5mM and while it also has some basal activity its key role is to 
respond to external stimuli. It therefore plays a greater role in effecting changes in 
glucose uptake. 
Kinetic studies have shown that insulin and other stimuli such as ischemia 
increase the Vmax of glucose transport. [Cushman, 1980 #11] This increase in Vmax can be 
caused by either an increase rate of turnover or by a greater availability of transporters at 
the cellular membrane. Membrane fractionation studies have established that most of the 
enhanced uptake is due to a shift of glucose transporters from intracellular pools where 
they are inactive to the sarcolemma where they can facilitate glucose uptake[Stephens, 
1995 #10] Unlike other insulin sensitive tissue such as adipocytes and skeletal muscle, 
glucose uptake in myocardium is stimulated by translocation of both GLUT4 and 
GLUT1 from intracellular pools to the sarcolemma in response to insulin and ischemia. 
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[Young, 1995 #79] However, the degree of translocation is greater for GLUT4. 
Translocation of glucose transporters to the T-tubule system also enhances uptake in 
muscle and is important in stimulating glucose uptake. [Dombrowski, 1996 #22; Roy, 
1996 #23] 
The AMP-activated Protein Kinase (AMPK) 
Myocardial ischemia causes an increase in glucose uptake through the 
translocation of the facilitative glucose transporters GLUT4 and GLUT1 from an 
intracellular pool to the sarcolemma through an undetermined mechanism. In addition, it 
causes activation of the AMP activated protein kinase (AMPK) [Kudo, 1995 #36; Kudo, 
1996 #24]. AMPK was first discovered over two decades ago and is highly preserved in 
all eukaryotes including mammals, fungi and plants. [Hardie, 1997 #28] AMPK has been 
proposed to play a central protein in the cellular response to changing metabolic 
conditions All mammals express a similar form of AMPK while in fungi and plants 
AMPK homologues such as SNP, a kinase involved in the regulation of cellular 
metabolism, are expressed. [Mitchelhill, 1994 #33] [Carling, 1989 #31] Unlike most 
kinases, AMPK serves not as a signal of extracellular messengers but rather as a way for 
the cell to respond to environmental stress causing a compromise of energetic and 
metabolic conditions within the cell. It has been described as a “fuel gauge” or a “low 
fuel warning system” for the cell signaling low levels of ATP and high energy 
phosphates caused by stress. [Hardie, 1994 #25] Stresses such as heat shock, hypoxia or 
oxidative stress impair the ability of mitochondria to rephosphorylate ADP to ATP 
causing an increase in the ADP to ATP ratio which in turn activates AMPK as AMP 
level rise. This causes an increase in the ADP to ATP ratio and an even larger increase in 
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the AMP to ATP ratio through the action of adenylate kinase which catalyses the 
conversion of ADP into AMP and ATP. The rise in AMP levels activates AMPK and 
inactivates regulatory enzymes in biosynthetic pathways and increases flux through 
catabolic pathways thereby preserving ATP for short term needs. [Corton, 1995 #26] 
Studies of purified enzyme show that AMPK is highly specific for AMP and the 
enzyme can only be activated by AMP or its analogs. AMP affects the AMPK system in 
four distinct ways (figure 1) [Hardie, 1997 #28; Corton, 1995 #26] First, it binds AMPK 
and causes direct allosteric activation. When the enzyme is in a phosphorylated state, 
allosteric activation by AMP causes a five fold increase in its activity. Second, AMP 
binds to dephosphorylated AMPK and makes it a better substrate for AMPK kinase 
(AMPKK). Phosphorylated AMPK has about a 50-fold greater activity than non- 
phosphorylated AMPK. Third, it binds to phosphorylated AMPK and makes it a worse 
substrate for protein phosphatase 2C (PP2C), an enzyme which is responsible for almost 
all the phosphatase activity of AMPK. Finally, AMP binds to and activates AMPKK. 
However, it is likely that AMPK activity is not determined by AMP alone. ATP 
levels are known to independently influence the activity of AMPK. [Hardie, 1997 #28; 
Corton, 1995 #26; Davies, 1989 #7] In muscle, the creatine kinase-phosphocreatine (Cr- 
PCr) system acts as an energy buffer to provide ATP during contraction and maintains 
the ATP:ADP ratio within myocytes. Recently, a decrease in the PCr:Cr ratio has been 
shown to increase AMPK activity in skeletal muscle. [Ponticos, 1998 #27] This is 
consistent with the role of AMPK in mediating a response to changes in energy state and 





this observation can be extended to cardiac muscle as well, given the similarity of the 
creatine system in cardiac muscle. 
AMPK was initially isolated from the liver as a kinase causing the 
phosphorylative deactivation of HMG-CoA reductase, the regulatory enzyme of sterol 
synthesis, and inhibiting sterol synthesis (and was dubbed HMG-CoA reductase kinase). 
[Ingebristen, 1978 #29] Subsequently, it was found to phosphorylate and inhibit acetyl 
CoA carboxylase and decrease malonyl-CoA. [Carling, 1987 #30] This decreases fatty 
acid synthesis while stimulating fatty acid oxidation by increasing camitine-palmitoyl 
transferase 1 (CPT1) and promoting entry of fatty acids into mitochondria, (figure 2) In 
the metabolism of glycogen, AMPK inhibits glycogen synthase and stimulates glycogen 
phosphorylase decreasing synthesis and stimulating breakdown. [Vincent, 1996 #45] The 
primary role of AMPK was therefore believed to be in the regulation of these synthetic 
pathways either through feedback or hormonal mechanisms. However, none of the 
products of these pathways has been shown to cause changes in it activity and it is not 
subject to hormonal regulation. These actions of AMPK should therefore be viewed in 
light of its role in responding to changing cellular metabolic conditions and it function in 
increasing flux through energy producing catabolic pathways while decreasing activity 
through energy consuming anabolic pathways. Further study is likely to reveal more 
roles for AMPK in the energy metabolism of the cell. 
The hypothesis that AMPK protects cells against stresses that deplete ATP 
suggests that it may be involved in many other processes. Studies in yeast have provided 
insight into other potential roles of AMPK. [Hardie, 1994 #25; Hardie, 1997 #28] 




































































































































































































that they are necessary for derepression of cytochrome oxidase genes required for 
oxidative metabolism and for expression of genes necessary for growth in the absence of 
glucose. In addition, they cause the phosphorylated inactivation of yeast acetyl-CoA 
carboxylase and are involved in cell cycle regulation. [Mitchelhill, 1994 #33] These 
findings suggest that the AMPK system is highly conserved and also plays a role in gene 
expression. Recently, the initial demonstration of AMPK activation of a mammalian 
gene has been made in hepatocytes where AMPK activation caused repression of the rat 
fatty acid synthase gene. [Foretz, 1998 #78] 
AMPK has three subunits named a (63kD), (3, and 5. (Davies) The a subunit is 
the catalytic subunit and shows a clear similarity to the SNF1 gene of the yeast 
saccharomyces cervisiae and other SNF1 related gene products from plants. It contains 
the site (Thr 172) for phosphorylation by AMPKK. [Hardie, 1997 #28] Two homologous 
isoforms of the a subunit, al and a2 have been identified. Recent studies have shown 
that the a2 variety has greater activity and is found in the highest levels in liver and 
skeletal and cardiac muscle. [Stapleton, 1996 #38] The specific distribution of the two 
may play a role in modulating the AMPK activity and thus, the tissue response to 
ischemia or other environmental stresses. 
Potential Role of AMPK Activation in Glucose Transport 
Two findings suggest that AMPK may be mediate the effects of myocardial 
ishcemia on glucose metabolism. First, AMP levels are known to rise during exercise in 
skeletal muscle [Hutber, 1997 #39] and in ischemic myocardium [Reibel, 1978 #40] and 
cause activation of AMPK in both skeletal muscle during exercise/contraction [Hutber, 
1997 #39] and myocardial ischemia. [Kudo, 1995 #36] Rising AMP levels are also 
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accompanied by lower concentrations of phosphocreatine. Both high AMP and lower 
phosphocreatine levels are known to activate AMPK. Second, ischemia/exercise induced 
increase in glucose uptake and GLUT 1 and GLUT 4 translocation is mediated through a 
pathway that is distinct from the PI3 kinase dependent translocation found with insulin. 
[Egbert, 1997 #41; Lund, 1995 #43] AICAR, a pharmacological activator of AMPK, 
also induced increase in glucose uptake that are independent of the PI3K 
pathway[Russell, 1998 #44; Hayashi, 1998 #50] and like ischemia are additive to insulin 
driven increases in glucose uptake [Russell, 1998 #44; Hayashi, 1998 #50] 
AICAR is a structural analog of adenosine (figure 3). It is taken up by cells and 
monophosphorylated by adenosine kinase to form AICARibotide or ZMP. ZMP 
activates AMPK mimicking the effects of AMP on AMPK without affecting the stores 
of ATP, ADP, and AMP and the relevant ratios that normally control AMPK activity 
[Henin, 1996 #48]. The activated AMPK has similar physiologic effects as when AMP 
levels rise including inhibition of ACC and decrease in malonyl-CoA [Merrill, 1997 #51] 
and increased fatty acid oxidation. 
Recently, AICAR has been shown to increase glucose uptake in perfused 
hindlimb muscles. [Merrill, 1997 #51] This laboratory has also demonstrated that 
incubation of isolated papillary muscles in AICAR causes enhancement of glucose 
uptake and translocation of GLUT4 glucose transporter [Russell, 1998 #44] These 
findings were limited by the in vitro nature of the study which allowed for the 
observation of the effects of AICAR on quiescent myocardial tissue not performing work. 
There was also no substrate competition and the uptake of deoxyglucose which does not 











estimate glucose uptake. Evidence of translocation was limited because it was only seen 
in qualitative immunoflorescence studies and in poor quality membrane fractions (only 5- 
6 fold enrichment of sarcolemmal membranes) [Russell, 1998 #44]. The findings from 
these membrane studies were further limited by the increase systemic lactate 
concentrations caused by the systemic AICAR infusion. 
In order to study the in vivo effects of AMPK activation by AICAR on glucose 
metabolism in vivo we infused AICAR in a selected region of the heart in dogs. This 
model offers several advantages. First, the direct infusion of AICAR into the coronary 
arteries allows a higher dose of AICAR and therefore greater activation of AMPK in 
myocardium without the systemic effects of high AICAR concentrations such as a 
buildup of lactate. This will enable a more clear interpretation of the effects of AMPK 
activation without the concern for the confounding effects of significant changes in 
substrate concentrations. Second, the large scale of the experiment allows for direct 
measurement of myocardial glucose uptake. Third, sufficient tissue can be obtained for 
membrane fractionation to study effects on glucose transporters and the use of a canine 
model also provides highly enriched membrane fractions. [Young, 1995 #79] Finally, 




Animal Preparation and Experimental Protocol 
Experiments were performed on fasting male mongrel dogs (40-60 lbs) according 
to a protocol approved by the Yale Animal Care and Use Committee. The animals (n=8) 
were anesthetized with sodium thiopental (70 mg/kg), intubated, and ventilated with 
halothane (1% to 2%), nitrous oxide (70%), and oxygen (30%) to maintain adequate 
anesthesia and oxygenation throughout the procedure. 
As previously described, [Shi, 1995 #16; Edwards, 1992 #15] the heart was exposed 
through a left lateral thoracotomy. Polyethylene catheters with 25 gauge needle ends 
were placed in the proximal left anterior descending coronary artery (LAD) for 
intracoronary infusion and in the cardiac veins draining the left circumflex coronary 
artery (LCX) regions and LAD for venous blood sampling. [Shi, 1995 #16] Doppler 
crystals were sutured to the epicardial surface to measure myocardial thickening within 
the LAD and LCX regions using fine suturing material. A micromanometer catheter was 
placed to measure left ventricular pressure and dP/dt. A left atrial catheter was placed for 
injection of microspheres to measure coronary blood flow. Core temperature was 
maintained with heating pads and covering sheets. 
After animal preparation, four baseline samples of arterial and LAD and LCX 
cardiac venous blood (4-5ml) were made over 20 minutes. Microspheres were then 
injected in order to measure blood flow. [Shi, 1995 #16; Edwards, 1992 #15] Small 
quantities of different isotopes were used for each time period. The microspheres do not 
affect flow or subsequent myocardial function. Hemodynamic parameters including heart 
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rate, aortic and left ventricular (LV) blood pressure, LV dP/dt, and cardiac output were 
recorded. Hemodynamic measures were recorded with data acquisition software 
(Dataflow, Crystal Biotech). AICAR was then infused into the proximal LAD at a rate 
of 12.5mg/min. (0.25ml/min) Repeat metabolic and hemodyanamic measurements were 
made at 30-45 minutes and at 75-90 minutes after the start of the AICAR infusion. The 
heart was then excised and samples (~0.5g) of tissue were taken from the central LAD 
and LCX regions and frozen in liquid nitrogen for AMPK activity determination. The 
remainder of the left ventricle was then placed in ice cold saline and utilized for 
membrane preparation and immunofluorescence as described below. 
Analytic Measurements 
Arterial and selected anterior and posterior cardiac venous blood was centrifuged 
and analyzed for plasma glucose and lactate concentrations with a glucose/lactate 
analyzer (Yellow Springs Instruments). Oxygen content in whole blood was measured 
with a hemoximeter (OSM 3, Radiometer America, Inc.). Plasma FFA was measured 
with a spectrophotometric assay (Waco) and AICAR concentrations were determined 
using a spectrophotometric assay which uses a diazotization coupling technique with N- 
(l-naphthyl)ethylenediamid. [Fujitaki, 1994 #42] The assay is adopted from established 
methods for the detection of primary aromatic amides and correlates to high degree 
(correlation coefficient of 0.98) with HPLC measurements and has a good sensitivity 
down to a concentration of 0.25|ig/ml. 
Myocardial AMP, ZMP, ADP and ATP concentrations in tissues were measured 
by HPLC according to a previously utilized protocol. [Sabina, 1982 #52] Approximately 
1 OOmg of frozen tissue was pulverized and homogenized in 4 times volume of 6% 
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perchloric, centrifuged at 3000g for 10 minutes at 4° C and neutralized with 3 M K 
HCO3. Samples were then filtered and diluted 1:10 before running on HPLC system 
(with Systom Gold software) eluting buffers of 5mM NH4H2PO4, pH 2.8 initially and 
changing to 750mM NH4H2PO4, pH 3.9 beginning at 14 min period of 35 minute run and 
increasing linearly. Desired peaks were identified and quantified by comparison with 
standards. 
Myocardial glycogen concentrations were determined using a method used by 
Walass et al. [Walaas, 1950 #46] Briefly, 20-40mg of tissue were solubilized in 200pJL 
30%KOH at 70° C and glycogen was precipitated overnight by the addition of lOOpL of 
6% Na2SC>4 and 700fiL of methanol. After centrifugation, the pellet was washed with 
methanol and resuspended in 500|iL 0.5 M sodium acetate (pH 4.8) with 2mg/mL 
amyloglucosidase. (sigma) After incubation for 90 min at 40° C the glucose 
concentration was determined. 
Myocardial glucose phosphate levels were measured using a spectrophotometric 
assay. [Lang, 1974 #85] Tissue extracts were mixed with 0.2M Tris, pH 7.5, 0.1M 
MgCb and 1% NADP and absorbance was measured both prior to and following the 
addition of the enzyme glucose-6-phosphate dehydrogenase (1 pig/pil). Various of 
concentrations of glucose-6-phosphate were assayed to estimate a standard curve. Citrate 
concentrations were measured using a spectrophotometric assay (Boerhinger Mannheim). 
PCA extracts were treated with citrate lyase, malate dehydrogenase, and lactate 
dehydrogenase which converted citrate to oxaloacetate and then lactate and in the process 
produced NAD+ from NADH and causing a change in absorbance. This change in 
absorbance was used to calculate the citrate concentration. Creatine phosphate was 
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measured from PCA extracts in 50mM triethanolamine, pH 7.5, 13mM NADP, 0.1M 
MgCh, 0.5M glucose, and 21mM ADP in the presence of creatine kinase, hexokinase and 
G6P dehydrogenase. [Heinz, 1983 #49] This reaction converts NADP+ to NADPH 
causing a shift in absorbance from which the creatine phosphate concentration can be 
calculated. 
Membrane Preparation and Characterization 
Left ventricular myocardium from the anterior region infused with AICAR and 
from the control posterior ventricular wall (approximately 25g each) was selected. The 
border zone between the two regions was discarded. Membrane fractions were prepared 
as described previously using differential and sucrose gradient centrifugation. [Russell, 
1998 #20; Young, 1995 #79] In brief, crude homogenates (20%wt/vol) were prepared in 
NaHC03 (lOmM) / NaN3 (5mM) buffer with a polytron and centrifuged at 1200g for 10 
minutes. The pellet was resuspended and rehomogenized and centrifugation was 
repeated. The supernatant (crude membrane fraction) was centrifuged at 190,000 g for 1 
hour, resuspended in a 25% sucrose solution and loaded onto a discontinuous sucrose 
gradient (25%, 30%, 35% wt/vol) and centrifuged for 18 hours at 150,000g. The 
sarcolemma fraction was collected from the upper half of the 25% sucrose layer The 
intracellular membrane fraction was collected from the 30%/35% interface. The 
membranes were collected and diluted 4-5 fold in NaHC03 (10mM/NaN3 5mM) and 
then centrifuged at 190,000g for 1 hour. All procedures were done at 4° C. The 
membranes were resuspended in Tris (50mM), pH 7.4 and stored at -70° C. There was 
no statistically significant difference in the protein yields between AICAR and control 
regions, (table 1) 
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Table la. Enrichment of Membrane Fractions 
Fraction Marker Enrichment vs. crudemembrane* 
Intracellular Ca~ ATPase Control: 8.8 (+/- 2.59) 
AICAR: 8.0 (+/-2.51) 
Sarcolemmal Na+/K+ ATPase Control: 239 (+/- 110) 
AICAR: 84 (+/- 14) 
Values are expressed as mean +/- SEM. * AICAR vs Control not statistically significant 
for both fractions. 
Table lb. Protein Yield Membrane Fractions 
Fraction Yield (fig)* 
Intracellular Control: 1022 (+/-285) 
AICAR: 955 (+/- 245) 
Sarcolemmal Control: 475 (+/- 57) 
AICAR: 490 (+/- 63) 
Values are expressed as mean +/- SEM. * AICAR vs Control not statistically significant 
for both fractions. 
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Membrane protein concentration was measured with a spectrophotometric assay 
(Bio-Rad Laboratories) using bovine serum albumin as a standard. Enrichment of 
fractions for the sarcolemma and sarcoplasmic reticulum proteins, Na+, K+-ATPase and 
Ca^-ATPase, respectively, was assessed by immunoblot analysis of the membrane 
fractions with monoclonal antibodies to the B-subunit of the Na+, K+-ATPase (gift from 
Dr. Michael Caplan) and the SERCA-2 calcium pump (Affinity Bioreageants, Inc). 
Immunoreactive protein was detected and quantified with -I-antimouse IgG 
(Amersham Co). Sarcolemmal membranes were highly enriched for the plasma 
membrane marker Na+, K+-ATPase (80-240 fold when compared with crude fractions) 
while the intracellular fractions were enriched for the intracellular marker Ca^-ATPase. 
(about 8 fold relative to crude membrane fraction). There was no statistically significant 
difference in these enrichments, (table 1) 
GLUT 4 and GLUT 1 Immunoblot Analysis 
Sarcolemma and intracellular membrane proteins (20pig) underwent SDS-PAGE 
on 10% and were transferred to PVDF membranes. [Young, 1995 #79] (Bio-Rad 
Laboratories) Membranes were blocked with 5% non-fat milk in PBS and then 
incubated with polyclonal GLUT4 that was partially purified in an IgG column (1:5000) 
or GLUT1 in whole serum (1:1000) antibodies with specific immunoreactivity in canine 
heart ( LHY1 ) overnight at 4° C. The membranes were washed and incubated with 125-I- 
protein A, washed again prior to autoradiography and then quantified using a gamma well 
counter (Packard Instruments). 

AMPK was assayed using a previously described method which measures the 
phosphorylation of a purified 17 amino acid peptide containing the consensus sequence 
(SAMS) for AMPK. [Winder, 1996 #34] Approximately lOOmg of tissue was 
homogenized in 5x volume of isolation buffer containing lOOmM Tris-HCl, pH 7.5, 
ImM EDTA, ImM EGTA, lmM DTT, ImM benzamidine, 400pg/ml trypsin inhibitor, 
50mM NaF, 5mM sodium pyrophosphate, 10% v/v glycerol. Homogenates were 
centrifuged at 14,000g for 30 min, polyethylene glycol 8000 (PEG) was added to the 
supernatant to achieve a concentration of 2.5% (w/v) and then centrifuged at 10,000g for 
10 min. PEG was then added to bring to a final concentration of 6% (w/v), centrifuged 
again at 10,000g, and the pellet was finally resuspended in lOOpl of homogenization 
buffer. Aliquots were taken to determine protein concentration and samples were stored 
in liquid nitrogen and stored for a maximum of 1-3 days. 
Isolated protein (2pg) was incubated in buffer containing 96mM Hepes-NaOH, 
pH 7.9, 192mM NaCl, 20%glycerol, 240mm SAMS, 2.4mmAMP, 5mM MgCf, 200p.M 
ATP with 200-400 dpm/pmol 32P ATP (Lopachuk 2) at 30°C for 5 minutes. Aliquots 
were then removed and spotted on phosphocellulose filter paper (Whatman P81), washed 
4 times with 150mM phosphoric acid over 30 minutes and once in acetone for 20 
minutes, dried and counted with liquid scintillation fluid . AMPK activity was 
determined after subtaraction of background activity. 
Calculations and Statistical Analysis 
Myocardial blood flow was calculated according to the following equation: 
Blood flow = (dpm/mg)'1*(dpm/ml)*(ml)*(sec)'1 
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The [ (dpm/mg) is obtained from counting samples of tissue, (dpm/ml) is calculated from 
the ratio of known quantity of isotope to measured quantity of blood, ml is injected 
volume, and time is also carefully measure (45 seconds)]. 
The myocardial uptake of glucose, lactate, and FFA were calculated as the 
product of the cardiac extractions (AV concentration difference) and the myocardial 
plasma flow. Plasma flow was in turn calculated from the blood flow and individually 
hemoglobin concentrations. Myocardial oxygen consumption was calculated as the 
product of oxygen extraction and the blood flow. The content of glucose transporters in 
either sarcolemma or intracellular membrane fraction was expressed as the binding per 
microgram protein calculated from the density (dpm/|ig protein) product of the dpm of 
l25-I-protein A and measured protein yield of that fraction (pg/g tissue) or expressed as 
the relative content of transporters of each fraction) 
All values are expressed as mean+/- SEM. Paired t test was used to compare 




Myocardial AICAR and Nucleotide Levels and AMPK Activity 
During AICAR infusion in the LAD, the venous concentrations in the LAD region were 
2510pM (+/- 78) as compared to 353|iM (+/- 55) in the LCX region at the end of the 90 
minute period (table 2) There was a wide range in concentrations, reflecting changes in 
flow. The medians were 1897(iM in the LAD region and 1 78jlxM in the LCX region. A 
value of 1399(iM in the LCX region (compared to 2280JJ.M in the LAD region) in one 
sample, probably due to the presence of venous collaterals that were inaccessible for 
suturing and separating, caused the average overall LCX region AICAR concentration to 
be much higher. The concentration of ZMP was 321pM (+/- 69) in the AICAR region 
and 158 pM (+/-34) (P < 0.05). There was no significant difference in the concentrations 
of AMP, ADP, or ATP levels (Table 2). 
AICAR infusion resulted in a significant 3-fold higher AMPK activity in the 
anterior region (73pmol/min/mg to 253pmol/min/mg) as compared to the LCX region 
which did not receive AICAR (figure 4). 
Subcellular Membrane Distribution of GLUT-1 and GLUT-4 
Analysis of western blots show that both GLUT-1 and GLUT-4 were found primarily in 
the intracellular compartment in regions of myocardium that did not receive AICAR. As 
determined by activity of the bands and yield of each fraction (see Methods), the 
sarcolemma contained 30% of GLUT-1 and 22% of GLUT-4, (figures 5, 6) 
In the region that received AICAR, there was evidence of translocation of both glucose 
transporters from the intracellular pools to the sarcolemma. The relative sarcolemma 
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distribution of GLUT-4 increasd 2-fold to 40% (P<.002) while that of GLUT-1 increased 
two-thirds to 50% (p<.001). (figures 5, 6) The ratio of sarcolemmal to intracellular 
transporter densities increased significantly for both GLUT-1 (0.75 to 1.3, p<0.0007) and 
GLUT-4 (0.35 to 0.68, p< 0.009). (table 3) 
Myocardial Metabolism in vivo 
Arterial concentrations of FFA, lactate, and oxygen content did not change during the 
local intracoronary infusion of AICAR . However, there was a significant decrease in 
glucose concentration following AICAR infusion at 45 minutes and 90 minutes, (table 4) 
The systemic arterial concentrations of AICAR were 93pM at 45 minutes and 123p.M at 
90 minutes. These AICAR concentrations are approximately 5% of the concentrations in 
the LAD bed and are not known to affect glucose concentration and is there not the likely 
cause of the drop in glucose concentration observed. Other systemic changes may be 
have caused a small hypoglycemic effect. Insulin levels were not determined. The 
AICAR region showed a 2-fold increase in myocardial glucose uptake, extraction, and 
arterial-venous difference (AVD) in the AICAR (LAD) regions when compared with the 
control (LCX) region after 90 minutes of AICAR infusion, (table 4, figure 8) There was 
a modest (approximately 30%) increase in FFA uptake, extraction, and AVD after 90 
minutes of infusion. There was a similar change after 45 minutes, although the AVD did 
not reach significance, (table 5) Prior to the administration of AICAR, the uptake, 
extraction, and AVD of glucose and FFA was similar in the two regions. Lactate and 
oxygen uptake showed no significant difference either in baseline period, at 45 minutes 
or at 90 minutes, (tables 6, 7) The myocardial uptake, extraction, and AVD of glucose 
and oxygen consumption were not significantly different in LCX (control) region or in 
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the LAD region following administration of AICAR in the LAD. However, there was 
significantly higher FFA extraction at 90 minutes of AICAR infusion when compared to 
baseline in the LAD region and a significantly lower lactate AVD in the LAD region at 
45 minutes and at 90 minutes of infusion when compared to baseline. 
Glycogen, citrate, G6P, and creatine phosphate levels were not significantly 
different in the AICAR and control regions.(table 2) 
Hemodynamics and Myocardial Thickening 
Infusion of AICAR in the LAD region had no effect on thickening fraction when 
compared to the control LCX region, (table 8, 9) However, there was statistically 
significant, 25% decrease in the thickening fraction of the LAD region following 90 
minutes of AICAR infusion, (table 9) Heart rate, mean arterial pressure, dP/dt and 
LVEDP were unchanged during AICAR infusion when compared to baseline 
Following AICAR infusion, there was a trend (P = 0.06) for higher blood flow in the 
AICAR perfused LAD region when compared with the LCX region. (Table 9) There 
was no change in blood flow following 45 minutes of AICAR infusion. (Table 8). 
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Table 2. Myocardial Tissue Concentrations of AICAR, 
Nucleotides, Glycogen, G6P, Citrate, and Creatine Phosphate 
Control AICAR (90min) 
AICAR (pM) 353 (+/-55) 2511 (+/- 78) * 
ZMP (pM) 158 (+/- 34) 321 {+1-69 ) * 
AMP (pM) 28 (+/- 548) 19 (+/- 119) 
ADP (pM) 1098 (+/-114) 1217 (+/- 183) 
ATP (pM) 3740 (+/-194) 4350 (+/- 249) 
Creatine Phosphate (mM) 9.0 (+/- 3.6) 8.4 (+/- 2.4) 
G6P (pM) 254 (+/-15) 271 (+/- 19) 
Citrate (pM) 535 (+/-35) 410 (+/-28) 
Glycogen (pM/g) 28 (+/-5.3) 32 (+/-4.5) 













Figure 4. AMPK activity in control and AICAR infused 
myocardium. Values are expressed +/- SEM (n=3). 
* P< 0.05 
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GLUT 1 (% SL) 
CONTROL AICAR 
Figure 5. Percentage of GLUT1 in sarcolemma 
in myocardium from control and AICAR- 
perfused regions. Values are mean +/- SEM. * 
P < 0.005 vs control region. 
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GLUT 4 (% SL) 
CONTTROL AICAR 
Figure 6. Percentage of GLUT4 in sarcolemma in 
control and AICAR perfused myocardium. Values 
















Table 3. Effect of AICAR on GLUT1 and GLUT4 Distribution 
in Intracellular (IC) and Sarcolemmal (SC) Fractions 
Control AICAR 
GLUT1 IC:SL 0.7 (.12) 1.3 (0.16)* 
GLUT1% SL 30 (6.4) 50 (4.7)* 
GLUT4 IC:SL 0.4 (0.09) 0.8 (0.05)* 
GLUT4% SL 22 (6.1) 39 (6.6)* 
Values are expressed as mean +/- SEM. * P< 0.005 vs Control. 
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Table 4 Effect of AICAR on Arterial Concentration, Arterial- 
Venous Difference,Extraction and Uptake of Glucose. 
Arterial A-V Difference 
LAD LCX 
Baseline 6.02 (0.24) 3.46 (0.067) 2.83 (0.058) 
45 min 5.52 (0.23)** 3.81 (0.052) 3.54 (0.054) 
90 min 5.37 (0.23)** 3.95 (0.059)* 2.09 (0.043) 
Extraction: LAD LCX 
Baseline 3.2 (1.01) 2.7 (0.96) 
45 minutes 3.8 (0.91) 3.7 (1.06) 
90 minutes 4.09 (1.08)* 2.2 (0.87) 
Uptake: LAD LCX 
Baseline 13.1 (4.3) 10.5 (3.8) 
45 minutes 13.5 (3.4) 9.9 (2.6) 
90 minutes 13.6 (3.3)* 5.9 (2.1) 
Arterial concentration and A-V difference in mM. Extraction is in %/100. Uptake is in 
pmol/lOOg/min. . Values are expressed as mean +/- (SEM). * P< 0.005 vs Control/ 













Figure 8. Uptake of glucose in myocardium from 
control and AICAR infused regions. Data are 
quantified as umol/IOOg/min. Values are mean +/- 




Table 5 Effect of AICAR on Arterial Concentration, Arterial- 
Venous Difference, Extraction and Uptake of FFA. 
Arterial A-V Difference 
LAD LCX 
Baseline 635 (106) 
45 min 527 (60) 
90 min 507 (43) 
174 (41) 163 (46) 
193 (42) 164 (32) 
207 (25)* 176 (26) 
Extraction: LAD LCX 
Baseline 27 (4.4) 22 (3.0) 
45 minutes 35 (4.3) 30 (3.4) 
90 minutes 42 (4.2)* & ** 34 (4.5) 
Uptake: LAD LCX 
Baseline 11.8 (2.5) 10.3 (2.0) 
45 minutes 13.3 (2.5) 9.1 (1.1) 
90 minutes 13.7 (2.0)* 10.0 (1.5) 
Arterial concentration and A-V difference in jiM. Extraction is in %/100. Uptake is in 
pmol/lOOg/min.. Values are expressed as mean +/- (SEM). * P< 0.005 vs Control. 
**P<0.05 vs Baseline. 
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Table 6 Effect of AICAR on Arterial Concentration, Arterial- 
Venous Difference, Extraction and Uptake of Lactate. 
Arterial A-V Difference 
LAD LCX 
Baseline 1.53 0.44 (0.074) 0.37 (0.067) 
45 min 1.46 0.23 (0.062)** 0.27 (0.063) 
90 min 1.62 0.24 (0.055)** 0.29 (0.065) 
Extraction: LAD LCX 
Baseline 29.4 (3.2) 26.8 (3.4) 
45 minutes 15.2 (3.7) 17.9 (3.4) 
90 minutes 13.9 (2.7)** 16.5 (4.1) 
Uptake: LAD LCX 
Baseline 27.5 (4.5) 23.1 (3.9) 
45 minutes 16.3 (3.9)** 16.8 (3.8)** 
90 minutes 12.3 (3.2)** 13.6 (3.2) 
Arterial concentration ana a-V amerence in mivi. extraction is in Vo/iuu. uptake is in 
|imol/100g/min.. Values are expressed as mean +/- SEM. * P< 0.005 vs Control. 





Effect of AICAR 
Consumption. 
on Arterial Oxygen Content and 
Arterial Oxygen Consumption 
LAD LCX 
Baseline 15 (1.5) 6.7 (1.5) 5.8 (0.7) 
45 min 15 (0.7) 6.6 (1.4) 5.6 (0.7) 
90 min 15 (0.9) 8.9 (0.8) 8.4 (0.9) 
Values are in ml/lOOg/min. Values are expressed as mean +/- SEM. * P< 0.005 vs 
Control. **P<0.05 vs Baseline. 
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Table 8. Myocardial Contactile Function and Hemodynamics 
during Baseline and after 45 Minutes of AICAR Infusion 
Baseline AICAR 
Thickening Fraction, % 
Control Region 17 (+/- 1.6) 17(4-/- 1.5) 
AICAR Region 20 (+/- 0.8) 19 (+/- 0.8) 
Heart Rate, bpm 113 (+/- 5.4) 112 (+/-6.4) 
Mean Arterial Pressure, mm Hg 82 (+/- 3.4) 83 (+/- 3.3) 
LVEDP, mm Hg 10 (+/- 1.2) 10(+/- 1.1) 
dP/dt, mm Hg/s 1297 (+/- 99) 1239 (+/- 99) 
Blood Flow, ml/g/min 
Control Region 1.01 (+/-0.08) 0.97 (+/- 0.22) 
AICAR Region 1.01 (+/- 0.08) 1.01 (+/- 0.17) 




Table 9. Myocardial Contactile Function and Hemodynamics 
during Baseline and after 90 Minutes of AICAR Infusion 
Baseline AICAR 
Thickening Fraction, % 
Control Region 17 (+/- 1.6) 16(+/- 2.7) 
AICAR Region 20 (+/- 0.8) 16 (+/- 0.5)* 
Heart Rate, bpm 113 (+/- 5.4) 117 (+/-6.8) 
Mean Arterial Pressure, mm Hg 82 (+/- 3.4) 79 (+/- 6.2) 
LVEDP, mm Hg 10 (+/- 1.2) 9 (+/- 1.3) 
dP/dt, mm Hg/s 1297 (+/- 99) 1062 (+/- 97)* 
Blood Flow, ml/g/min 
Control Region 1.01 (+/-0.08) 0.81 (+/- 0.14) 
AICAR Region 1.01 (+/- 0.08) 1.01 (+/- 0.17)** 





AMPK Activation, Stimulation of Glucose Transport and Transporter 
Translocation 
This study demonstrates two important findings. First, it shows that activation of AMPK 
by AICAR results in a two-fold increase in myocardial glucose uptake in vivo. Second, it 
demonstrates that this increase in glucose uptake is associated with translocation of heart 
GLUT 4 and GLUT 1 glucose transporters from an intracellular pool to the sarcolemma 
suggesting that the increased glucose uptake is at least in part mediated by transporter 
translocation. Since myocardial ischemia and hypoxic stress or contraction in skeletal 
muscle are also known to activate AMPK and stimulate glucose uptake through glucose 
transporter translocation, this study supports the hypothesis that ischemia mediated 
changes in glucose may also be mediated by this kinase. 
AICAR, an intermediate in the purine biosynthetic pathway, is taken up by cells 
and phosphorylated to form ZMP which mimics the effects of intracellular AMP causing 
allosteric activation of AMPK and promoting phosphorylation and covalent activation of 
AMPK by AMPK kinase. [Corton, 1995 #26] In this study, local intracoronary infusion 
of AICAR achieved concentration of approximately 2mM in the venous blood draining 
from the infused region. AICAR was taken up by the heart and was phosphorylated to 
form ZMP. The myocardial ZMP concentration averaged 310p,M which approximates 
the concentration causing the half maximal activation of AMPK in vitro. [Henin, 1996 
#48] Significantly, the concentrations of the substrates which normally determine AMPK 
activity, AMP, ATP, and ADP as well as creatine phosphate were unchanged indicating 
that the changes in AMPK activity were not an indirect effect of AICAR altering the 
. 
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energetics of cardiac myocytes but rather a likely direct effect through conversion to 
ZMP. 
Our findings demonstrated a 2-3 fold increase in the myocardial glucose uptake 
associated with AMPK activation during local intracoronary AICAR infusion in vivo. 
This is comparable to the 3-4 fold increase in glucose uptake observed during low flow 
ischemia in the same canine model using a similar protocol and measurement techniques 
in our laboratory. [Young, 1995 #79] Other studies of AMPK stimulation by AICAR 
also found similar effects on glucose uptake. In perfused hindlimbs, AMPK stimulation 
by AICAR led to a several fold increase in glucose uptake. [Merrill, 1997 #51] In vivo, 
systemic infusion of AICAR at a rate of 7.5 mg/kg achieved an average ZMP 
concentration of 350pM, similar to the concentration in the AICAR perfused region in 
our study, and stimulated skeletal muscle glucose uptake two fold. [Bergeron, 1998 #86] 
In recent in vitro studies, we observed that incubation of isolated quiescent rat papillary 
muscles in ImM AICAR caused a two-fold increase in deoxyglucose uptake. [Russell, 
1998 #44] Thus the findings in the intact heart in this study are congruent with these 
earlier studies and further demonstrate the enhancement of myocardial glucose uptake in 
hearts performing a physical workload while also subject to the influence of circulating 
hormones. 
This study found that AICAR infusion is associated with translocation of 
myocardial GLUT4 and GLUT1 from intracellular pools to the sarcolemma. This 
suggests that, in myocardium, AICAR stimulates glucose uptake by increasing the 
number of facilitative glucose transporters available at the sarcolemma. We have 
recently found that AICAR also stimulates translocation of GLUT4 to the sarcolemma 
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using immunoflorescence in quiescent rat papillary muscles. These studies were in non¬ 
working myocardium and in an artificial hormonal and substrate milieu. This the first 
demonstration of AICAR induced translocation of GLUT4 in vivo and the initial 
evidence that AMPK stimulation by AICAR causes translocation of GLUT1 as well. 
AICAR caused an increase in the sarcolemmal content of GLUT4 from 22% to 
40%. Exercise or skeletal muscle and myocardial ischemia also cause translocation of 
glucose transporters. In our previous studies, [Young, 1995 #79] low flow ischemia led 
to a doubling of the distribution of GLUT4 in the sarcolemma increasing from 15% to 
30%. While it had been suggested that only GLUT4 translocation is involved in the 
response of muscle to exercise/contraction GLUT1 also plays a role in cardiac muscle. 
[Douen, 1990 #65; Hayashi, 1997 #17] GLUT1 is only found in the sarcolemma of 
adipocytes and skeletal muscle and is not thought to be “recruitable” in these tissues. 
However, in myocardium we have previously found that GLUT1 is responsive to 
ischemia though to a lesser extent than GLUT4. Low flow ischemia caused the 
proportion of GLUT1 in the sarcolemma to increase by 41% to 58%. This is somewhat 
less than the effect of AICAR and AMPK activation which increased GLUT1 
sarcolemma from 30% to 50%. [Young, 1995 #79] This provides further evidence that 
GLUT1 plays a unique role in myocardium in that it is recruitable and responds to stimuli 
to increase uptake of glucose. This is likely due to the large metabolic demands of 
myocardium. 
AMPK Activation in Muscle 
AICAR infusion stimulated AMPK activity by three fold. There is evidence 
which suggests that AMPK activation plays a key role in the response to oxidative stress 
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in both skeletal and cardiac muscle whether during contraction/exercise or ischemia. 
The highest levels of mRNA are found in skeletal and cardiac muscle. [Verhoweven, 
1995 #53] In skeletal muscle of rats, prolonged exercise led to a several fold activation of 
AMPK and a subsequent inactivation of ACC and repression of malonly CoA. [Winder, 
1996 #34] In perfused working rat hearts subject to global ischemia, there was a large 
increase in AMP levels and a 2-3 fold activation of AMPK. [Kudo, 1995 #36] AMPK 
activity remained high even after reperfusion reflecting, perhaps the continuing effects of 
AMPK phosphorylation. [Kudo, 1995 #36; Kudo, 1996 #24] Many other studies have 
demonstrated a stimulation of AMPK in response to exercise/contraction or ischemia 
[Hutber, 1997 #39; Vavvas, 1997 #80] 
Given that both ischemia and AICAR infusion stimulate glucose uptake and 
translocation of GLUT4 and GLUT1, it is intriguing to consider that ischemia induced 
translocation of glucose transport and is mediated through AMPK. While the 
mechanism through which ischemia in myocardium and exercise/contraction stimulate 
glucose uptake and glucose transport translocation is not known, it is characterized by 
several observations demonstrating that it is distinct from the well studied insulin 
regulated increase in glucose uptake and glucose transporter translocation. Insulin binds 
to the a-subunit of the insulin receptor which leads to phosphorylation of the (3-subunit 
and increased tyrosine kinase activity. Tyrosine kinase phosporylation of the 
intracellular insulin receptor substrate-1 (IRS-1) then causes activation of 
phosphatidylinositol-3-kinase(PI3 K). (figure 9) [Holman, 1997 #54] This kinase is 
inhibited by wortmannin and the action of insulin in stimulating glucose uptake and 
translocation is also inhibited in both skeletal muscle and cardiac muscle. [Lee, 1995 
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#61; Russell, 1998 #44; Hayashi, 1998 #50]This is in contrast to the ischemia mediated 
and exercise/contraction mediated increase in glucose uptake [Russell, 1998 #44; 
Bergeron, 1998 #86] and translocation in skeletal muscle which is not influenced by 
PI3K inhibition by wortmannin. Wortmannin did not block the stimulation of glucose 
uptake by AICAR in skeletal muscle [Russell, 1998 #44; Bergeron, 1998 #86] and in 
isolated papillary muscles. [Russell, 1998 #44] A second observation which suggests a 
distinct pathways in insulin and ischemia/exercise stimuated glucose uptake is the 
additive nature of insulin and ischemia/contraction. AICAR and ischemia are not 
additive but AICAR and insulin are additive in skeletal muscle. [Bergeron, 1998 #86] 
Finally, our study bolsters the hypothesis because pharmacological AMPK stimulation 
was shown to cause translocation and increased transport in vivo in physiologic 
conditions. 
Other pathways for the ischemia mediated glucose transport have been 
hypothesized. Due to the role of PI3K in insulin mediated on glucose, a potential role 
for the kinase in ischemia/contraction was hypothesized in muscle. However, studies of 
PI3K inhibition suggest that it is not a mediator in ishcemia/contraction. [Egbert, 1997 
#41; Lund, 1995 #43] Protein kinase B (Akt) has been identified as a downstream target 
for PI3K in the insulin mediated GLUT4 translocation and it may serve as a target for 
AMPK as well. [Hayashi, 1997 #17] Since calcium plays a key role in muscle 
contraction, it has also been proposed as a mediator of translocation. [Holloszy, 1996 
#19] While calcium has been shown to increase glucose transport in isolated muscle and 
blockade of calcium release from sarcoplasmic reticulum blocks glucose transport, 
calcium stimulated glucose transport does not share one a key characteristic of 

47 
exercise/ischemia mediated glucose uptake—it inhibits insulin induced glucose transport 
in contrast to exercise/ischemia induced glucose transport which is additive to insulin. 
[Draznin, 1987 #60; Lee, 1995 #61] 
Several kinases have been proposed as mediators of exercise/contraction 
stimulation of glucose uptake. Inhibition of PKC by phorbol esters has been shown to 
decrease contraction stimulated glucose transport in skeletal muscle in vitro. [Cleland, 
1989 #62] Exercise also activates the mitogen-activated protein kinase (MAP kinase). 
[Aronson, 1997 #64] But this mechanism is unlikely given recent that demonstration that 
pharmacological blockade of MAP kinase does not influence contraction stimulated 
glucose transport in vitro . [Hayashi, 1998 #50] Other kinases proposed to be involved in 
GLUT4 translocation include the c-Jun NH2 terminal kinase and p38 kinase. [Hayashi, 
1997 #87] These kinases may mediate the effects of ischemia and AICAR in stimulating 
GLUT4 translocation, (figure 9) 
Other changes that result from ischemia may also mediate the effects of ischemia 
Nitric oxide is released during skeletal muscle contraction and inhibition of nitric oxide 
synthase has been demonstrated to inhibit contraction mediated glucose transport but not 
insulin stimulated glucose transport. [Kapur, 1998 #57; Balon, 1997 #55] Other potential 
regulators of glucose transport include bradykinin [Kishi, 1998 #88] and kallikrein and 
adenosine. [Han, 1998 #56; Law, 1988 #58] While nitric oxide, bradykinin, and 
kallikrein are potential mediators of AICAR induced stimulation of glucose transport, it 
is unlikely since no potential mechanism whereby AICAR influences them has been 
identified. Since AICAR may increase local concentrations of adenosine and is 
structurally similar to adenosine, it is possible that its actions may be mediated by acting 
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Figure 9 Schematic presentation of the potential mechanisms of insulin and ischemia induced GLUT4 
translocation. Yellow circles are representations of insulin sensitive GLUT4 vesicles with specific 
makers such as Rab4 (orange). Pink circles represent ischemia and/or AMPK sensitive GLUT4 vesicles. 
IR is the insulin receptor. Blue represents GLUT4 transporters. 
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on adenosine receptors. However, AICAR is not known to act on adenosine receptors 
and inhibition of these receptors does not affect AICAR stimulation of glucose uptake. 
[Russell, 1998 #44] 
Downstream Mechanisms of GLUT4 Translocation 
The downstream mechanisms responsible for AMPK mediators are unclear. 
Studies from the insulin mediated transport indicate that there are many potential 
mechanisms by which AMPK may effect glucose translocation. GLUT4 cycles between 
the plasma membrane and intracellular compartments with most staying intracelluarly in 
the basal state. [Kandror, 1996 #67] Stimulation of glucose uptake can be effected either 
through an increase in the rate of GLUT4 vesicle exocytosis or by a decrease in 
endocytosis. [Stephens, 1995 #10] Insulin acts largely by stimulating exocytosis, causing 
a 10-20 fold increase in exocytosis compared to only a 2-3 fold decrease in the rate of 
endocytosis. GLUT1 is distributed more evenly between the intracellular compartment 
and the sarcolemma and plays a smaller role in altering glucose transport in response to 
extracellular signals. [Young, 1995 #79; Fischer, 1997 #21] Insulin causes a more modest 
stimulation of GLUT1 and exercise has been reported not to influence GLUT1 in skeletal 
muscle but we have previously shown that ischemia in myocardium, like AICAR, does 
cause translocation of GLUT1, though to a more modest degree. [Young, 1995 #79] 
GLUT4 Vesicles 
There is evidence which suggests that GLUT4 vesicles are heterogeneous. The 
additive nature of exercise and insulin mediated effects on glucose transport and GLUT4 
translocation suggest there may be further or separate pools of GLUT4 vesicles that are 
more responsive to specific stimuli. [Douen, 1990 #65] Novel membrane fractionation 
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techniques in cultured adipocytes have identified distinct intracellular locations or pools 
of glucose transporters, one responsive to exercise and another more responsive to 
insulin. [Hayashi, 1997 #17; Coderre, 1995 #63] Rab4, a GTP binding protein involved 
in formation, targeting, and fusion of vesicles by acting as a molecular switch by 
interconversion, from a GDP-bound form to a GTP-bound form [Van der Sluijs, 1992 
#89] is redistributed by insulin but not by exercise. [Hayashi, 1997 #17; Sherman, 1988 
#90] It is possible that GLUT4 carrying vesicles have unique receptors making them 
more sensitive to particular stimuli. 
Regardless of whether GLUT4 vesicles are segregated by responsiveness to 
stimuli or not, GLUT4 transporters require specific signals to be properly targeted for 
intracellular storage. [Pessin, 1999 #66] Recent studies suggest that the cytoplasmic C- 
terminus of GLUT4 contains a dileucine motif whose absence leads to accumulation of 
GLUT4 in the plasma membrane[Verhey, 1995 #82]. This sequence has been shown to 
be involved in internalization and while similar motifs responsible for sequestration have 
not been identified, morphologic and kinetic studies suggest they are present in the 
GLUT4 cytoplasmic C-terminus. [Pessin, 1999 #66] 
GLUT4 Exocytosis 
A recent review proposes two major, overlapping mechanisms whereby insulin 
and other stimimuli can regulate GLUT4 exocytosis . [Pessin, 1999 #66] The first, 
“retention model” (figure 10) suggest that GLUT4 vesicles participate in the 
constituitively recycling endosomal system with regulation of exocytosis by regulation of 
GLUT4 vesicles through specialized “retention receptors” that control their entry into the 
endosomal system. GLUT4 protein is localized in small vesicles and tubulovesicular 
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structures with lesser amounts in the trans-Golgi network, clathrin-coated vesicles and 
endosomes. [Rodnick, 1992 #68; Slot, 1991 #69] GLUT4 vesicles and tubulovesicular 
are found adjacent to endosomes underlying plasma membrane. [Pessin, 1999 #66] For 
insulin induced translocation, the insulin-responsive aminopeptidase (IRAP), also known 
as vpl65, may act as a retention receptor. IRAP is known to probably co-localize with 
GLUT4 vesicles and displays some homology with the GLUT4 C-terminus. [Kandror, 
1994 #73] In addition, introduction of the cytoplasmic domain of IRAP results in plasma 
membrane translocation of GLUT4. [Waters, 1997 #91] Despite the evidence supporting 
the role of the recycling endosomal system and sequestering, retention receptors, there 
are other findings which suggest that this model does not account for all the regulation of 
iGLUT4 trafficking. GLUT4 containing vesicles can be differentiated from the 
constituitively recycling endosomal system. GLUT4 vesicles are enriched in the v- 
SNARE (vesicle SNAP receptors) protein , VAMP2 but not the VAMP3 isoform present 
in the constituitively recycling endosome population. [Martin, 1998 #71] Furthermore, 
ablation of the endosomal population as tracked by the transferrin receptor suggest that 
insulin-stimulated GLUT4 translocation can occur independent of the endosomal system. 
This finding with insulin may also be true with ischemia. 
Protein complexes in the GLUT4 vesicle compartment such as the v-SNARE 
VAMP2 suggest that a synaptic-like mechanism similar to that found in the vesicle 
trafficking regulation of neurotransmitters may regulate GLUT4 vesicle transport. 
[Pessin, 1999 #66] (figure 11) v-SNAREs pair with their matching receptor complexes at 
the target membrane (called t-SNAREs for target SNAP receptors). Interaction between 






Figure to. Schematic illustration of retention hypothesis of GLUT4 trafficking. GLUT 4 
vesicles are sequestered by association with retention receptors (RR). Insulin or other 
stimuli such ischemia or AMPK activation can cause dissociation from RR and entry of 
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Figure \ \. Schemtic presentation of the hypothesized synaptic model of GLUT4 trafficking. 
GLUT4 vesicles are localized to small synaptic like vesicles and larger tubulovesicular compart¬ 
ments in equilibrium. Both have the v-SNARE VAMP2. GLUT4 translocation can be induced by 
interaction of VAMP2 with t-SNARE complex. (Blue figures represent GLUT4. GLUT4 at plasma 
membrane not shown). 
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determining trafficking and formation of complexes required for membrane fusion 
[Pessin, 1999 #66] . VAMP2 has been identified on GLUT4 vesicles and may act as the 
v-SNARE protein while studies using blocking antibodies, dominant interfering mutants 
and peptide inhibitors suggest that several proteins (including syntaxin 4 and 
SNAP23/Syndet) act as the t-SNARE proteins. Muncl8c and Synip have recently been 
shown to bind to syntaxin 4 and may be part of the complex that regulates the interaction 
with VAMP2. Binding of Muncl8c to syntaxin 4 prevents its binding to VAMP2 and an 
increase in expression of Muncl8c inhibits insulin-stimulated GLUT4 translocation. 
While the precise role of Synip has not been delineated, it interaction with syntaxin 4 is 
known to be regulated by insulin. 
Role of G-Proteins and GLUT4 Endocytosis 
There is a role for G-proteins in GLUT4 trafficking but the specific mechanisms 
have not been elucidated. GTPyS causes GLUT4 translocation [Pessin, 1999 #66] and G- 
protein coupled receptors linked to Gq can also induce GLUT4 translocation. [Kishi, 
1998 #88] Signalling intermediates such as Grb2 involved in G-protein signal 
transduction are also known to interact with IRS 1, a key intermediary of insulin 
stimulated translocation through PI3K. [Holman, 1997 #54] 
G-proteins may have an especially significant role in GLUT4 endocytosis. In the 
basal state, GLUT4 in plasma membrane is in coated pit regions and disruption of 
clathrin has established a role for clathrin-mediated edocytosis in GLUT4 internalization. 
GTPase dynamins are essential to this process and in addition to GTPase sites have 
domains which interact with signaling intermediates such inositol phospholipids and 




Figure 12- The internalization of GLUT4 occurs through a dynamin-dependent mechanism. After 
translocation, GLUT4 accumulates in clathrin-coated (orange) invaginations of the plasma membrane. This 
occurs through the interaction of of GLUT4 with complexes such as AP2 (red circle). Dynamin (green 
rectangle) is recruited to thesese structures and is required for the intracellular clathrin coated vesicles. 
These vesicles rapidly lose their coat structure and are available for translocation or to repopulate the 
intracellular pool of GLUT4 vesicles. 
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GLUT4 endocytosis and may serve as a target of AMPK phosphorylation, (figure 
12) Insulin has been reported to induce tyrosine phosphorylation of dynamin [Baron, 
1998 #75]and microinjection of a dynamin peptide encompassing anphiphysin binding 
sites prevents GLUT4 edocytosis and cause accumulation in the sarcolemma. [Volchuk, 
1998 #77]Expression of a dominant interfering mutant of dynamin has also been shown 
to prevent GLUT4. [Al-Hasani, 1998 #76] This GTPase may thus be a target for AMPK 
phosphorylation. 
Fate of glucose 
While AICAR infusion increased myocardial glucose uptake, our findings do not 
define the fate of the glucose. Once in the cell as G6P there are four potential fates of 
glucose: glycogen synthesis, glycolysis, glucose oxidation or the pentose phosphate 
shunt. G6P concentrations were unchanged in the AICAR regions, indicating that any 
increase in glucose conversion to G6P was balanaced by increased distal metabolism. 
Although AMPK inhibits glycogen synthase and stimulates glycogen phosphorylase in 
liver effectively decreasing synthesis and increasing breakdown, [Gillespie, 1992 #92] it 
does not affect glycogen synthase in musle but still stimulates glycogen phosphorylase 
leading to increased glycogenolysis. [Young, 1996 #93] However, in the rat, intravenous 
AICAR infusion does no affec skeletal muscle glycogen. [Bergeron, 1998 #86] But in 
myocardium it appearst to increase muscle glycogen. [Russell, 1998 #44] The latter effect 
may be due to preferential flux of glucose into glycogen which may occur due to the 
increase in arterial lactate concentrations accompanying AICAR infusion. [Russell, 1998 
#44] We saw a fall in arterial lactate suggesting that the glucose was not released as an 
end product of glycolysis. 
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Oxygen uptake was not stimulated in the AICAR region. Increased glucose 
oxidation could be expected to stimulate oxygen uptake, especially in light of the 
enhanced FFA uptake that is also likely to have been oxidized (see below). The energy 
content of the cell as measured by creating phosphate and ATP did not change. These 
findings suggests that AICAR did not stimulate glucose oxidation. A potential fate of 
glucose is to enter the pentose phosphate shunt to provide NADPH for reductive 
biosynthesis. The activity of this pathway is very low in muscle [Stryer, 1995 #84] and 
unlikely to be the primary fate of the additional glucose that is taken up. It is important 
to note that if the glucose did not become metabolized through a single pathway, the 
measurement techniques we used may have been inadequate to record several small 
changes. 
Effect on FFA 
Our study found a small increase in FFA uptake following AICAR infusion. This 
is consistent with previous studies which showed a stimulation of FFA entry into 
mitochondria due to an increase in CPT1 activity caused by a decrease in malonyl-CoA 
levels which resulted from the phophorylation of ACC and a 50% increase in FFA 
oxidation. [Kudo, 1995 #36] While we did not measure FFA oxidation or triglyceride 
synthesis it is likely that the additional FFA was oxidized through the phosphorylative 
inhibition of ACC. However, we did not see an increase in oxygen uptake. 
Hemodynamics and Functional Effects 
While there was a trend for higher blood flow in the AICAR infused region, the 
overall myocardial contractility and cardiac output were significantly depressed 
following region infusion of AICAR. Though much lower rates of systemic AICAR 
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infusion were used, earlier investigators had found that AICAR had no functional effects 
on non-ischemic myocardium [Young, 1991 #94; Gruber, 1989 #95] and improved 
cardiac function in ischemic myocardium. [Young, 1991 #94; Gruber, 1989 #95] 
Clinical studies also show a beneficial effect of AICAR on myocardial function. 
A meta-analysis of 5 international randomized trials showed that intravenous infusion of 
AICAR (O.lmg/kg/min) following surgery reduced perioperative myocardial infarction 
by 27% and decreased the incidence of cardiac death by 50% in the postoperative period. 
[Mangano, 1997 #96] Another study found that AICAR improved ventricular function in 
pacing-induced ishcmia. [de Jonge, 1997 #97] 
The mechanism for any functional effect of AICAR in ischemic myocardium is 
not known but a role for increases in local concentrations of adenosine has been 
postulated. [Gruber, 1989 #95] Despite the structural homology of AICAR with 
adenosine, AICAR is not known to act on adenosine receptors and we did not measure 
tissue or venous concentrations of adenosine. However, the functional effects that we 
found are consistent with the known vasodilatory and negative inotropic effects of 
adenosine receptor stimulation in myocardium. [Shryock, 1997 #98] Other investigators 
[Gruber, 1989 #95] had not found an increase in adenosine concentrations in non¬ 
ischemic tissues. 
Limitations of Study and Future Directions 
The functional findings are limited by a lack of control animal experiments to 
separate the potentially confounding effects of infusion and additional operative time 
under anesthesia with open chest. While it was not a major aim of our study to 
investigate these effects, additional studies with saline infused controls would clarify 

59 
these findings. The control used in this study (LAD vs LCX) is not ideal because the two 
arterial beds are not completely separated and communicate via collaterals. Moreover, 
the extended period of study may allow AICAR to accumulate and cause systemic 
effects. However the concentration of AICAR in the LAD (AICAR) bed was more than 
seven fold higher than in the LCX (control) bed and more than 20-fold higher than in the 
systemic circulation. The control bed was also not infused with saline and this may also 
be a confounding variable. However, the rate of infusion is about 0.5% of the normal 
canine coronary blood flow (0.25ml/min vs. 50ml/min) and unlikely to cause significant 
disturbances in flow parameters. 
The link between AMPK activation and glucose transporter translocation cannot 
be unambiguously established. We verified that AICAR infusion did lead to a 
concentration of ZMP that is known to cause significant activation of AMPK and that the 
enzyme was stimulated by infusion. However, while AICAR is known to activate 
AMPK and has not been shown to cause any other effects on the cellular energy state, it 
is possible that it has unidentified effects which may confound our findings. Experiments 
with inhibitors of AMPK such as the ser-thr kinase inhibitor 5-iodotuberidon or genetic 
techniques to suppress or overexpress the AMPK gene in myocardium would provide 
further support for a role of AMPK in ischemia mediated changes in glucose transport. 
This study provides the background necessary to pursue these investigations. 
Conclusion 
This study suggests that metabolic stress such as ischemia stimulate glucose 
uptake by translocation of GLUT4 and GLUT1 through a mechanism that involves 
AMPK. Additional studies are necessary to delineate the downstream effectors that lead 
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to translocation. This system may also mediate other the cellular and tissue responses to 
ischemia. Augmented stimulation of the system by AICAR or other potential stimulators 
may enhance myocardial function during acute episodes of ischemia or in the long term, 
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